Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10
    patrik.dehaes@thrombogenics.com

    Chris Buyse, CFO
    Tel: +32-16-75-13-10
    chris.buyse@thrombogenics.com

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44-(0)207-638-95-71
    amber.bielecka@citigatedr.co.uk'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)...   MSC , a healthcare performance improvement company ... appointment of Mary Beth Loesch to President ... experience preparing companies for rapid growth and market expansion, ... of Corporate Development and Healthcare. In that role, she ... well as corporate strategy and marketing. Previously, Loesch served ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... April 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), ... sclerosis (MS), today,announced that the independent Data Safety ... on-going MAESTRO-03 U.S. pivotal phase III,clinical trial of ... and,recommended that the trial continue., This was ...
... Bionovo Inc.,(Nasdaq: BNVI ) will present findings on ... BN107 and BN108 at the American Association of,Cancer Research ... in San,Diego, CA, April 12 - 16, 2008., ... cell,apoptosis (cell death) induced by BN107 and BN108. As ...
... ST. JOSEPH, Mich., April 15 GeneGo, Inc., ... The Scripps,Translational Science Institute has joined the MetaMiner ... build the first systems,biology and pathway analysis platform ... will vote on deliverables that will include,disease specific ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research 2The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium 2
(Date:8/27/2014)... of studies have shown that excessive iron ... Parkinson,s disease. Previous studies from Chunyan Guo ... China have shown that baicalin prevented iron ... metal transporter 1 expression, and increased ferroportin ... rotenone-induced Parkinson,s disease rats. However, the relationship ...
(Date:8/27/2014)... that can be found in both unprocessed and processed ... Denmark have been infected with Listeria from ... The bacterium is notoriously difficult to fight because it ... in its surroundings, says Associate Professor Birgitte Kallipolitis, University ... of Biochemistry and Molecular Biology, she has published a ...
(Date:8/26/2014)... over a colony of harmful bacteria, biofilms make ... protected in a biofilm pose a significant health ... to treatment, and biofilm-protected bacteria account for some ... and are 50 to 1,000 times more resistant ... essence, we may have stumbled onto a magic ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... energy produced by cars, machines, and industry around the world ... but researchers have found a new way to make "thermoelectric" ... amounts of energy. And it,s based on a device ... Chemists at Oregon State University have discovered that simple ...
... team has turned their newly developed 3-D microscope technology ... use. U of A engineering professor Dileepan ... system called Virtual Reflected-Light Microscopy. The technology consists of ... that moves the objects being photographed and software programs ...
... Paul Kenis and James Slauch have been named ... university,s most talented teachers, scholars and researchers. Kenis, ... in the field of micro fluidics and the development ... health. These tools include the creation of evaporation-based ...
Cached Biology News:Microwave ovens a key to energy production from wasted heat 2Microwave ovens a key to energy production from wasted heat 3University of Illinois faculty members named University Scholars 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: